Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich… - The Lancet, 2019 - thelancet.com
Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
E Marilly, J Cottin, N Cabrera, C Cornu, R Boussageon… - Diabetologia, 2022 - Springer
Aims/hypothesis Cardiovascular outcome trials (CVOTs) have demonstrated the benefits of
sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, serious adverse drug …
sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, serious adverse drug …
Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of …
WC Tsai, SP Hsu, YL Chiu, JY Yang, MF Pai, MJ Ko… - BMJ open, 2022 - bmjopen.bmj.com
Objectives To assess the cardiovascular and renal efficacy and safety of sodium-glucose
cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods We searched …
cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods We searched …
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
M Lugner, N Sattar, M Miftaraj, J Ekelund… - Cardiovascular …, 2021 - Springer
Background Major prospective randomized clinical safety trials have demonstrated
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review …
Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2)
inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to …
inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to …
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
DSH Lin, JK Lee, CS Hung, WJ Chen - Diabetologia, 2021 - Springer
Aims/hypothesis Several cardiovascular outcome trials on sodium–glucose cotransporter 2
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
H Hussein, F Zaccardi, K Khunti… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To compare the efficacy and tolerability of sodium‐glucose co‐transporter 2 inhibitors
(SGLT‐2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in adults with type 2 …
(SGLT‐2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in adults with type 2 …
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
DK McGuire, WJ Shih, F Cosentino… - JAMA …, 2021 - jamanetwork.com
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …